Amgen may see $3B+ in additional taxes; EQRx, AbCellera ink antibody development deal
Alongside the release of its Q2 results late Tuesday, Amgen also signaled that it’s defending what could be a sizeable chunk of cash that it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
